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Brief Definitive Report
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extracellular tau in vivo
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Tau is primarily a cytoplasmic protein that stabilizes microtubules. However, it is also found
in the extracellular space of the brain at appreciable concentrations. Although its presence
there may be relevant to the intercellular spread of tau pathology, the cellular mechanisms
regulating tau release into the extracellular space are not well understood. To test this in
the context of neuronal networks in vivo, we used in vivo microdialysis. Increasing neuronal
activity rapidly increased the steady-state levels of extracellular tau in vivo. Importantly,
presynaptic glutamate release is sufficient to drive tau release. Although tau release occurred within hours in response to neuronal activity, the elimination rate of tau from the
extracellular compartment and the brain is slow (half-life of 11 d). The in vivo results
provide one mechanism underlying neuronal tau release and may link trans-synaptic spread
of tau pathology with synaptic activity itself.
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David M. Holtzman:
holtzman@neuro.wustl.edu
Abbreviations used: AD, Alz
heimer’s disease; ISF, inter
stitial fluid; LDH, lactose
dehydrogenase; NFT, neuro
fibrillary tangle; NMDA,
N-Methyl-d-aspartic acid; PTX,
picrotoxin; TTX, tetrodotoxin.

Tau is a major component of neurofibrillary
tangles (NFTs) in Alzheimer’s disease (AD) and
other disorders known as tauopathies. The burden and distribution of NFTs correlate well
with cognitive decline in AD (Arriagada et al.,
1992; Bancher et al., 1993). In AD, NFTs are
prominent early in entorhinal cortex and later
appear in anatomically connected brain regions
(Braak and Braak, 1995). Cell to cell transmission
is one hypothesis accounting for this phenomenon (Mohamed et al., 2013). Previous studies
suggest that certain forms of tau released into
the extracellular space can enter cells and induce
further tau aggregation (Clavaguera et al., 2009;
Frost et al., 2009; Guo and Lee, 2011; Kfoury
et al., 2012; Iba et al., 2013). Tau pathology appears to spread trans-synaptically from entorhinal
cortex to hippocampus before marked neurodegeneration (de Calignon et al., 2012; Harris
et al., 2012; Liu et al., 2012). Studies suggest
that tau can be secreted into the extracellular
space from neurons independently from cell
death (Chai et al., 2012; Karch et al., 2012). In
addition, the elevation of tau in cerebrospinal
fluid is associated with AD and is linked to A
deposition (Jack et al., 2013; Maia et al., 2013).
Despite the fact that extracellular tau may initiate
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synaptic spread of tau pathology, the mechanisms
regulating neuronal release of extracellular tau are
not fully understood.
We hypothesized that neuronal activity regulates release of tau from neurons. To test this
idea in the setting of mature neuronal networks,
we used in vivo microdialysis and analyzed the
kinetics of release and clearance of extracellular
tau in brain interstitial fluid (ISF).
RESULTS AND DISCUSSION
Increasing neuronal activity
increases ISF tau in vivo
The technique of in vivo microdialysis enables
the hourly measurement of endogenous ISF
tau from wild-type mice. During microdialysis,
mice are awake and freely moving, allowing for
the assessment of mechanisms regulating ISF
tau in the context of normally functioning neuronal networks. We reasoned that if neuronal
activity is a major regulator of tau release into
the ISF, altered activity would result in a change
© 2014 Yamada et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/
licenses/by-nc-sa/3.0/).
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and not due to an increased level of total tau proteins inside
cells (Fig. 2 E).
To further assess whether the treatments we administered
to increase neuronal activity were not causing cellular damage
or death, further assays were performed. Neuronal damage,
including loss of membrane integrity, causes nonspecific release of intracytoplasmic proteins such as lactose dehydrogenase (LDH).Thus, we measured LDH activity in ISF of P301S
human tau transgenic mice in the presence of PTX administered by reverse microdialysis. PTX treatment resulted in a
two- to threefold increase in ISF human tau in P301S human
tau transgenic mice (Fig. 2 F), similar to the increase seen in
mouse tau in wild-type mice. However, PTX did not increase
LDH activity in ISF (Fig. 2, G and H). The administration of
pilocarpine is known to cause seizures and excitotoxic injury
in brain. Systemic administration of pilocarpine resulted in
seizure activity within 30 min in all mice. It also resulted in an
increase of ISF tau by 10–15-fold from baseline (Fig. 2 F).
Unlike PTX, pilocarpine significantly increased LDH activity,
confirming that excitotoxic injury releases cytoplasmic proteins nonspecifically (Fig. 2, G and H). Pilocarpine administration rapidly induced abnormal activation of neurons, as is
evident by seizure phenotypes observed within 30 min in all
mice. Nevertheless, the release of LDH by pilocarpine was
only observed much later after seizures began (7.5 h later;
Fig. 2 G). These findings strongly suggest that nonspecific release of cytoplasmic proteins by excitotoxic brain injury is a
much slower process than the activity-dependent release of
tau in ISF. Consistent with this data, pilocarpine, but not PTX,
increased degenerating neurons stained by Fluoro-Jade C
(unpublished data). Collectively, the data strongly suggests
that the increase of ISF tau by PTX is due to enhanced neuronal activity and not due to neuronal injury or death caused
by excitotoxic injury.

Figure 1. Depolarization increases tau
in ISF. (A–C) Microdialysis experiments were
performed in hippocampi of wild-type mice.
After baseline collection, the regular perfusion
buffer was switched to high K+ perfusion
buffer (administration indicated by gray box).
After 1 h, the buffer was switched back to
normal perfusion buffer (wash out) and ISF
collection was continued. Glucose (A), lactate
(B), and tau (C) in ISF were measured. (n = 5;
*, P < 0.05; **, P < 0.01). For mice studied in
A–C, each mouse was investigated independently. Any treatment effects were compared
with baseline values within each mouse. Error
bars represent SEM. (D) Representative EEG
trace from one of three mice during depolarization with high K+ perfusion buffer.
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in the level of preexisting extracellular tau in vivo. After baseline tau measurement, hippocampal neurons were locally depolarized by briefly exposing them to high K+ perfusion
buffer via reverse microdialysis. Consistent with an elevation in
neuronal activity, depolarization rapidly decreased glucose by
46% (Fig. 1 A) and increased lactate by 171% (Fig. 1 B) in ISF.
Lactate and glucose rapidly returned to baseline levels after
wash out. ISF tau increased by 68% from baseline in response
to high K+ (Fig. 1 C) in the first hour and continued to increase by up to 152% during the wash out period. Once peak
tau concentrations were reached, ISF tau returned to baseline
levels over hours. To determine the levels of neuronal activity
in response to high K+, we used intrahippocampal EEG recording to assess extracellular field potentials during high K+
depolarization.The infusion of high K+ resulted in EEG bursting activity (Fig. 1 D).
To stimulate neurons at lower frequency and avoid any
potential cell injury or death caused by higher activity such as
is found in prolonged seizures, picrotoxin (PTX), a noncompetitive GABAA receptor antagonist was locally and continuously infused in hippocampus via reverse microdialysis at
relatively low doses. In contrast to EEG bursting activity
caused by high K+, the low dose of PTX used in this study
only produced occasional spikes, as assessed by EEG, but no
epileptiform activity or seizures (Fig. 2 A). This is similar to
what we have observed previously (Cirrito et al., 2008; Bero
et al., 2011). PTX decreased glucose by 33% and increased
lactate by 342% (Fig. 2, B and C) consistent with increased
neuronal activity. PTX also rapidly increased ISF tau by 149%
within hours (Fig. 2 D). In contrast to the brief depolarization
by high K+, the increase of ISF tau was maintained while
neurons were activated by infusion of PTX. PTX did not
alter tau levels in hippocampal tissue lysates, further confirming that increase of ISF tau is due to the release from neurons

Br ief Definitive Repor t

To examine how ISF tau can be regulated by the increasing neuronal activity to different degrees, we administered
increasing doses of N-Methyl-d-aspartic acid (NMDA) in the
hippocampus. NMDA administered via reverse microdialysis
at doses of 1–40 µM has dose-dependent effects on excitatory
JEM Vol. 211, No. 3

neuronal activity—measured by EEG—without causing cell
death or neurodegeneration (Fig. 2 I;Verges et al., 2011). Consistent with the EEG data, NMDA resulted in a dose-dependent
increase of ISF tau (Fig. 2 J), suggesting that the degree of
neuronal activity can determine ISF tau levels. Given that
389
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Figure 2. Neuronal activity and synaptic activity increase tau in ISF. (A) Representative EEG trace from one of three mice during depolarization
with high K+ perfusion buffer. 25 µM PTX was delivered directly into the hippocampus of wild-type mice via reverse microdialysis (indicated by dashed
line). (B–D) Glucose (B), lactate (C), and tau (D) in ISF was measured (n = 6/group). (E) Hippocampal tissue tau levels after PTX reverse microdialysis
(n = 6/group). (F and G) 25 µM PTX was delivered directly into the hippocampus of P301S human tau transgenic mice via reverse microdialysis for 6 h
(n = 5). After 6-h washout, the mice were given an i.p. injection of 325 mg/kg pilocarpine hydrochloride (indicated by arrows). Human tau (F) and LDH (G)
activity in ISF was measured. The mean LDH activity was compared between groups (H; *, P < 0.05). (I) Representative EEG trace from one of three mice
during various doses of NMDA infusion. (J) The effects of various doses of NMDA delivered by reverse microdialysis on ISF tau was measured (n = 6;
*, P < 0.05; ***, P < 0.001). (K) The effects of the highly selective mGluR2/3 antagonist LY341495 (administered by reverse microdialysis) on ISF tau was
measured (n = 6 for LY341495, n = 7 for vehicle). Error bars represent SEM. For mice studied in B–D, F–H, and J–K, each mouse was investigated independently.
Any treatment effects were compared with baseline values within each mouse.

The effect of TTX on ISF tau levels in vivo
We next asked whether inhibiting neuronal activity alters ISF
tau.To this end, we infused the voltage-gated sodium channel
blocker tetrodotoxin (TTX). Surprisingly, TTX did not cause
a decrease of basal ISF tau within the window of microdialysis
(Fig. 3 A). In contrast,TTX rapidly decreased endogenous A
in the ISF by 35% (Fig. 3 B), as we previously reported (Cirrito
et al., 2005). Confirming that TTX does have an effect on tau
release, pre-administration of TTX blocked the NMDAinduced increase in ISF tau (Fig. 3 C).
The in vivo turnover rate of tau
To try to explain the lack of acute responsiveness of basal ISF
tau to blocking neuronal activity, we note that the balance
between cellular release and clearance determines the steadystate levels of proteins measured by microdialysis. Inhibiting
synaptic activity reduces ISF A production and release. Reduced A release can be visualized quickly, as the in vivo

half-life of A is 2 h (Cirrito et al., 2005), leading to the
rapid elimination of A by clearance mechanisms. Unlike A,
tau is known as a very stable protein (Price et al., 2010). This
raised the possibility that slow turnover might prevent the
ability to see an effect of TTX on inhibition of basal ISF tau
release over hours.
To examine the clearance of soluble tau in vivo, the turnover rate of tau was kinetically analyzed using transgenic
mice, which express a non-aggregating form of human tau
(anti-aggregant mice: 2N4R-tau with K280/PP mutations).
The expression of human tau in these mice can be quickly
switched off by doxycycline (Eckermann et al., 2007). These
mice do not develop tau pathology, allowing us to examine
the clearance of soluble tau without the influence of tau aggregates (Van der Jeugd et al., 2012; Hochgräfe and Mandelkow,
2013). To be able to analyze the elimination of ISF tau
chronically for up to 18 d by microdialysis, mice were divided
into five groups where human tau expression was switched
off for the predetermined length of time. One cohort of mice
was not exposed to doxycycline to determine the initial
human tau levels before tau switch-off. In vivo microdialysis
was performed in all groups and levels of ISF tau were assessed over 2 d in each mouse. ISF human tau levels were determined by ELISA. The absolute ISF human tau levels after
switch-off were normalized to the level of ISF human tau in
the mice without switch-off. Soluble human tau in the hippocampus where ISF tau was collected was also analyzed at
the end of microdialysis.
Switch-off specifically decreased human tau in hippocampal lysates in a time-dependent manner without changing endogenous murine tau levels, confirming the specificity
of switch-off. ISF human tau was also decreased over time,
whereas lactate levels did not decrease (Fig. 4, A and B). The
elimination of tau followed first-order kinetics and the halflife was calculated as 11.1 d for soluble tau in hippocampus
and 10.9 d for ISF tau, respectively. The clearance rate of tau
in hippocampal tissue was comparable to a previous report
assessing total tissue tau (Price et al., 2010; Fig. 4, C and D).

Figure 3. TTX does not cause an acute decrease of ISF tau. After baseline ISF tau collection, 5 µM TTX was delivered via reverse microdialysis (indicated by dashed line). The effect of TTX on ISF tau (A; n = 10) and ISF endogenous Ax-40 (B; n = 7; *, P < 0.05) is shown. The effect of preadministration
of TTX on ISF tau in the presence of 0.4 µM NMDA (C; n = 6–7 per group; *, P < 0.05) is also shown. Both TTX and NMDA were administered by reverse
microdialysis in C. Error bars represent SEM. Each mouse studied in A–C was investigated independently. Any treatment effects were compared with
baseline values within each mouse.
390
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the EC50 of NMDA receptors is 35 µM in vitro, NMDA concentrations of 0.4–4 µM delivered via reverse microdialysis in
this study should activate only a small percentage of the receptors (Verges et al., 2011). Nevertheless it is sufficient to
drive an 70% increase of ISF tau, suggesting that excitatory
neuronal activity has a significant impact on ISF tau.
Metabotropic glutamate receptors 2/3 (mGluR2/3) are
expressed at the presynaptic terminal and regulate glutamate
release. The inhibition of these receptors enhances glutamate
release from the presynaptic terminals (Cirrito et al., 2008).To
specifically ask whether the presynaptic excitatory neuronal
activity modulates ISF tau, LY 341495, a highly selective
mGluR2/3 antagonist was infused into the hippocampus via
reverse microdialysis and ISF tau was simultaneously measured. LY 341495 caused a rapid increase of ISF tau by 80%
(Fig. 2 K). This data links presynaptic excitatory neuronal activity with tau release. Collectively, these data strongly suggest
that excitatory neuronal activity can rapidly alter the steadystate levels of extracellular tau levels in vivo.

Br ief Definitive Repor t

This observation suggests that extracellular, ISF tau has a much
longer in vivo turnover rate than A.Thus, even if a substance
such as TTX decreased endogenous tau release, it would be
expected to take several days to see such a change.
In summary, our present study describes a mechanistic link
between neuronal activity and extracellular tau in vivo. In this
context, we note a very recent in vitro study using primary
cultured neurons (Pooler et al., 2013) in which neuronal activity is also linked to increased tau release. Importantly, we found
that neuronal activity rapidly alters the steady-state levels of
preexisting ISF tau in vivo. Furthermore, presynaptic glutamate
release by mGluR2/3 antagonist LY 341495 is sufficient to increase ISF tau, suggesting that presynaptic excitatory neuronal
activity is linked to tau release. Although neuronal activity increases tau release within hours, tau clearance, which is distinct
from diffusion to adjacent areas of the brain with lower tau, requires many days.This slow turnover will delay the elimination
of extracellular tau and, as a consequence, it may affect its aggregation and synaptic transmission of tau pathology. Intriguingly, not only tau but also many other intraneuronal proteins
have been identified in the extracellular space of brains, although the mechanism of release of these cytoplasmic proteins
remains unknown (Lee et al., 2005). Among them are proteins
such as -synuclein, which contributes to cell to cell transmission of Parkinson’s disease pathology (Luk et al., 2012). The
mechanism we report here may have broader implications to
elucidate mechanisms of release and prion-like spread of intracellular proteins involved in neurodegeneration.
MATERIALS AND METHODS
Compounds. PTX, TTX, NMDA, and pilocarpine were obtained from
Sigma-Aldrich. LY341495 was obtained from Abcam.
Animals. All animal studies performed were reviewed and approved by the
Animal Studies Committee at Washington University. 3–5-mo-old male and
JEM Vol. 211, No. 3

female P301S human tau transgenic mice and wild-type littermates on B6C3
background were used for microdialysis studies. Regulatable transgenic mice
expressing anti-aggregant human full-length tau mice (Tau 2N4R with mutations deltaK280/PP) on C57BL/6 background were generated as previously
described (Eckermann et al., 2007). Mice were screened for the expression of
exogenous tau by in vivo bioluminescence imaging of luciferase assay
(Hochgräfe and Mandelkow, 2013). Individuals with signal intensities >107 p/s
were selected for switch-off experiments (Van der Jeugd et al., 2012).
In vivo microdialysis. In vivo microdialysis experiments to assess brain ISF
tau levels from awake and freely moving mice were developed with modifications of our previously described method (Yamada et al., 2011). A guide
cannula (Eicom microdialysis) was stereotactically implanted in the left hippocampus under isoflurane anesthesia, and cemented. After implantation of
the cannula and dummy probes (Eicom microdialysis), mice were habituated
to microdialysis cages for one more day. After this recovery period, a 2-mm
1,000-kD cut-off AtmosLM microdialysis probe (Eicom) was inserted
through the guide cannula. A probe was connected to a microdialysis peristaltic pump with two channels (MAB20; SciPro), which was operated in a
push-pull mode. As a perfusion buffer, 25% human albumin solution (Gemini
Bio Inc.) was diluted to 4% with artificial CSF (aCSF; 1.3 mM CaCl2, 1.2 mM
MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3, and 122 mM
NaCl, pH 7.35) on the day of use and filtered through a 0.1-µm membrane.
For 100 mM high K+ stimulation, 97 mM KCl in aCSF was substituted for
an equal amount of NaCl. Normal perfusion buffer was switched to high K+
perfusion buffer for 1 h. Before microdialysis sample collection, a pump was
run at the maximum flow rate for at least 1 h. For ISF collection from wildtype mice, 1 µl/min was used. For ISF human tau collection from transgenic
mice expressing anti-aggregant human full-length tau (deltaK280/PP),
0.5 µl/min was used.To avoid tissue damage, the experimental window was set
from 6 to 48 h after probe implantation.We confirmed that within this timeframe, ISF tau and Ax-40 concentrations remain stable under constant light
conditions. ISF samples were collected in a refrigerated fraction collector
(SciPro) and analyzed by ELISA. 25 µM PTX, 5 µM TTX, 0.4–40 µM
NMDA, and 100 µM LY341495 were delivered into ISF via reverse microdialysis. For NMDA reverse microdialysis, each dose of NMDA was administrated
for 5 h in ascending fashion. To assess the effect of TTX on the increase of
ISF tau by NMDA, 5 µM TTX was delivered by reverse microdialysis for 12 h,
followed by co-infusion of 0.4 µM NMDA and 5 µM TTX for 12 h.
391
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Figure 4. The turnover rate of tau in
hippocampus and ISF is low. Human tau
expression in anti-aggregant mice was
switched off for the indicated lengths of time
by doxycycline, and human tau (black circle)
and murine tau (white square) levels in
hippocampus were measured by ELISA
(A; n = 5–7/group/time point; **, P < 0.01;
***, P < 0.001; ****, P < 0.0001). Human tau
(black circle) and lactate (white square) in
ISF after switch-off were measured by ELISA
(B; n = 4–5/group/time point; **, P < 0.01). The
plot of the common logarithm of percent tau
in hippocampal lysates or ISF versus time was
linear in both groups studied. The slope from
the linear regressions from log (% tau) versus
time was used to calculate the half-life (t1/2)
of elimination for tau from hippocampus
(C) and ISF (D). Each mouse studied in A–D
was investigated independently. Any treatment effects were compared with baseline
values obtained from mice studied at time
zero. Error bars represent SEM.

Switch-off experiments. 16–17-mo-old transgenic mice expressing antiaggregant human full-length tau (deltaK280/PP) were randomly divided into
five groups. One cohort of mice was not exposed to doxycycline-containing
food pellets (200 mg/kg; Bio-serv) and ISF was collected for 48 h (0 day
groups). Other cohorts of mice received doxycycline-containing food pellets
for 2, 6, 8, or 16 d, respectively before microdialysis. On day 2, 6, 8, or 16,
in vivo microdialysis was started and ISF samples were collected for 48 h. During
microdialysis, mice were given doxycycline-containing food pellets. Brains
were collected on day 4, 8, 10, or 18, respectively, at the end of microdialysis
experiments. Hippocampus where microdialysis probes were inserted was
used to determine intracellular human tau levels in hippocampus. Percentages of brain human tau, ISF human tau, and ISF lactate were normalized by
the mean concentration in 0 day groups.
Pilocarpine injection. Mice received a low dose of methyl scopolamine
(1 mg/kg) to reduce peripheral cholinergic effects. After 30 min, mice were given
i.p. injection of 325 mg/kg pilocarpine hydrochloride. All animals injected
with pilocarpine displayed motor seizure phenotype. 15 min after pilocarpine
injection, the mice were injected with pentobarbital to terminate seizures.
Tau ELISA. The tau concentration in media of brain slice culture and ISF
of wild-type mice was analyzed in a tau sandwich ELISA with Tau-5 as a
coating antibody (gift from L. Binder, Northwestern University, Evanston,
IL) and biotinylated BT-2 (Thermo Fisher Scientific) as a detection antibody
as previously described (Yamada et al., 2011). Human tau in ISF and brains
was measured by a human tau-specific sandwich ELISA with Tau-5 as a coating antibody and biotinylated human specific HT-7 (Thermo Fisher Scientific) as a detection antibody. Murine endogenous tau in brains was measured
by a sandwich ELISA with HJ9.2 as a coating antibody and biotinylated tau
antibodies (HJ8.7) as a detection antibody. HJ8.7 and HJ9.2 are in-house
mouse monoclonal antibodies that recognize the N-terminal domain of tau
(epitope of HJ8.7: residues 118–122; epitope of HJ9.2: residues 4–8). The
human tau levels in samples were determined by subtracting background signals from wild type in Tau-5/HT7 ELISA.
Ax-40 ELISA. Ax-40 ELISA was done as previously described (Cirrito
et al., 2008). Background determined by signal from the microdialysis perfusion buffer was subtracted.
Glucose and lactate measurements. Glucose and lactate concentration
in ISF and media was determined by YSI2700 biochemistry analyzer (YSI
Life Sciences). Glucose was used as a marker of substrate utilization, and lactate was used as a marker of neuronal activity (Bero et al., 2011).
Brain extraction. Mice were perfused with chilled PBS-heparin. Brains were
dissected for biochemical analysis and kept at 80°C until analyzed.To analyze
tau after PTX infusion, left (exposed to PTX by reverse microdialysis) and right
hippocampi were dissected at 4.5 h after PTX infusion where both ISF lactate
and tau showed the highest increases from baseline.Tau in hippocampal lysates
was determined by Tau-5/BT2 ELISA. Contralateral hippocampus (right) was
used as a control. In switch-off experiments, hippocampus was weighed and
homogenized in RAB buffer (100 mM MES, 1 mM EDTA, 0.5 mM MgSO4,
750 mM NaCl, 20 mM NaF, and 1 mM Na3VO4, supplemented by protease
392

inhibitors [Complete; Roche] and phosphatase inhibitors [PhosSTOP; Roche]).
The samples were centrifuged at 50,000 g for 20 min at 4°C.The supernatants
were collected as RAB soluble fractions.The pellets were further homogenized
by RIPA buffer (150 mm NaCl, 50 mm Tris, 0.5% deoxycholic acid, 1% Triton
X-100, and 0.5% SDS–25 mm EDTA, pH 8.0, supplemented by protease inhibitor [Complete; Roche] and phosphatase inhibitor [PhosSTOP; Roche]).
Total tau in both RAB and RIPA soluble fractions were combined and used as
brain soluble tau.
The calculation of half-life. The elimination of tau in brain lysates and
ISF followed first-order kinetics. Thus t1/2 for tau was calculated with the
slope, k, of the linear regression (t1/2 = 0.693/k, where k = 2.303k) as we
previously reported (Castellano et al., 2011).
LDH assay. LDH activity in ISF was determined by Lactate Dehydrogenase
Activity Assay kit (Sigma-Aldrich). The final measurement [(A450)final] for
calculating the enzyme activity was normalized by the baseline activities.
After normalization, mean LDH activity during the 6-h PTX treatment and
in the last 6-h pilocarpine treatment were compared with baseline.
Statistical analysis. Data in figures represent mean ± SEM. All statistical
analysis was performed using Prism (version 5.04 for Windows; GraphPad
Software). Analysis of the effects of drugs compared with vehicle control was
done by two-way ANOVA with repeated measures. The comparison between baseline and post-treatment was done by paired Student’s t test. The
comparison of multiple groups was done by one-way ANOVA. Values were
considered significant if P < 0.05.
This work was supported by Japan Society for the promotion of Science (K. Yamada)
and the Tau consortium (D.M. Holtzman and E.-M. Mandelkow).
The authors declare no competing financial interests.
Submitted: 11 August 2013
Accepted: 27 January 2014

REFERENCES

Arriagada, P.V., J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman. 1992.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 42:631–639. http://dx.doi.org/10
.1212/WNL.42.3.631
Bancher, C., H. Braak, P. Fischer, and K.A. Jellinger. 1993. Neuropathological
staging of Alzheimer lesions and intellectual status in Alzheimer’s and
Parkinson’s disease patients. Neurosci. Lett. 162:179–182. http://dx.doi
.org/10.1016/0304-3940(93)90590-H
Bero, A.W., P. Yan, J.H. Roh, J.R. Cirrito, F.R. Stewart, M.E. Raichle,
J.-M. Lee, and D.M. Holtzman. 2011. Neuronal activity regulates the regional vulnerability to amyloid- deposition. Nat. Neurosci. 14:750–756.
http://dx.doi.org/10.1038/nn.2801
Braak, H., and E. Braak. 1995. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol. Aging. 16:271–278. http://dx.doi.org/10
.1016/0197-4580(95)00021-6
Castellano, J.M., J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W.
Patterson, A.M. Fagan, J.C. Morris, K.G. Mawuenyega, C. Cruchaga,
et al. 2011. Human apoE isoforms differentially regulate brain amyloid peptide clearance. Sci. Transl. Med. 3:89ra57.
Chai, X., J.L. Dage, and M. Citron. 2012. Constitutive secretion of tau
protein by an unconventional mechanism. Neurobiol. Dis. 48:356–366.
http://dx.doi.org/10.1016/j.nbd.2012.05.021
Cirrito, J.R., K.A. Yamada, M.B. Finn, R.S. Sloviter, K.R. Bales, P.C. May,
D.D. Schoepp, S.M. Paul, S. Mennerick, and D.M. Holtzman. 2005.
Synaptic activity regulates interstitial fluid amyloid- levels in vivo.
Neuron. 48:913–922. http://dx.doi.org/10.1016/j.neuron.2005.10.028
Cirrito, J.R., J.-E. Kang, J. Lee, F.R. Stewart, D.K. Verges, L.M. Silverio,
G. Bu, S. Mennerick, and D.M. Holtzman. 2008. Endocytosis is required for synaptic activity-dependent release of amyloid- in vivo.
Neuron. 58:42–51. http://dx.doi.org/10.1016/j.neuron.2008.02.003
Neuronal activity regulates extracellular tau | Yamada et al.

Downloaded from https://rupress.org/jem/article-pdf/211/3/387/640812/jem_20131685.pdf by Washington University In St. Louis Libraries user on 07 December 2019

EEG recording. Electrical activity was recorded in the hippocampus surrounding the microdialysis probe similar to Cirrito et al. (2008). In brief, bipolar recording electrodes (Teflon-coated, stainless steel wire, 0.0055-in coated
OD; A-M Systems) were attached to the shaft of the microdialysis guide cannula (BR-style; Bioanalytical) with Super-Fast Epoxy Resin (Elmer’s). Electrodes extended 1 mm from the tip of the guide, so that the electrode tip was
located at the center of the 2-mm microdialysis membrane. EEG activity was
assessed using a P511K A.C. pre-amplifier (Grass Instruments), digitized with a
DigiData 1440 Data Acquisition System (Molecular Devices), and recorded
digitally using Axoscope 10.2. Compounds were administered directly to the
brain via reverse microdialysis at a flow rate of 1 µl/min.

Br ief Definitive Repor t

JEM Vol. 211, No. 3

J. Biol. Chem. 287:19440–19451. http://dx.doi.org/10.1074/jbc.M112
.346072
Lee, H.-J., S. Patel, and S.-J. Lee. 2005. Intravesicular localization and exocytosis of -synuclein and its aggregates. J. Neurosci. 25:6016–6024. http://
dx.doi.org/10.1523/JNEUROSCI.0692-05.2005
Liu, L., V. Drouet, J.W. Wu, M.P. Witter, S.A. Small, C. Clelland, and K.
Duff. 2012. Trans-synaptic spread of tau pathology in vivo. PLoS ONE.
7:e31302. http://dx.doi.org/10.1371/journal.pone.0031302
Luk, K.C., V. Kehm, J. Carroll, B. Zhang, P. O’Brien, J.Q. Trojanowski,
and V.M.-Y. Lee. 2012. Pathological -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science.
338:949–953. http://dx.doi.org/10.1126/science.1227157
Maia, L.F., S.A. Kaeser, J. Reichwald, M. Hruscha, P. Martus, M. Staufenbiel,
and M. Jucker. 2013. Changes in amyloid- and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.
Sci. Transl. Med. 5:re2.
Mohamed, N.-V., T. Herrou, V. Plouffe, N. Piperno, and N. Leclerc.
2013. Spreading of tau pathology in Alzheimer’s disease by cell-to-cell
transmission. Eur. J. Neurosci. 37:1939–1948. http://dx.doi.org/10.1111/
ejn.12229
Pooler, A.M., E.C. Phillips, D.H.W. Lau, W. Noble, and D.P. Hanger. 2013.
Physiological release of endogenous tau is stimulated by neuronal activity.
EMBO Rep. 14:389–394. http://dx.doi.org/10.1038/embor.2013.15
Price, J.C., S. Guan, A. Burlingame, S.B. Prusiner, and S. Ghaemmaghami.
2010. Analysis of proteome dynamics in the mouse brain. Proc. Natl.
Acad. Sci. USA. 107:14508–14513. http://dx.doi.org/10.1073/pnas
.1006551107
Van der Jeugd, A., K. Hochgräfe, T. Ahmed, J.M. Decker, A. Sydow, A.
Hofmann, D. Wu, L. Messing, D. Balschun, R. D’Hooge, and E.-M.
Mandelkow. 2012. Cognitive defects are reversible in inducible mice
expressing pro-aggregant full-length human Tau. Acta Neuropathol.
123:787–805. http://dx.doi.org/10.1007/s00401-012-0987-3
Verges, D.K., J.L. Restivo, W.D. Goebel, D.M. Holtzman, and J.R. Cirrito.
2011. Opposing synaptic regulation of amyloid- metabolism by
NMDA receptors in vivo. J. Neurosci. 31:11328–11337. http://dx.doi
.org/10.1523/JNEUROSCI.0607-11.2011
Yamada, K., J.R. Cirrito, F.R. Stewart, H. Jiang, M.B. Finn, B.B. Holmes,
L.I. Binder, E.-M. Mandelkow, M.I. Diamond, V.M.-Y. Lee, and D.M.
Holtzman. 2011. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31:13110–13117. http://dx.doi.org/10.1523/
JNEUROSCI.2569-11.2011

393

Downloaded from https://rupress.org/jem/article-pdf/211/3/387/640812/jem_20131685.pdf by Washington University In St. Louis Libraries user on 07 December 2019

Clavaguera, F., T. Bolmont, R.A. Crowther, D. Abramowski, S. Frank, A.
Probst, G. Fraser, A.K. Stalder, M. Beibel, M. Staufenbiel, et al. 2009.
Transmission and spreading of tauopathy in transgenic mouse brain.
Nat. Cell Biol. 11:909–913. http://dx.doi.org/10.1038/ncb1901
de Calignon,A., M. Polydoro, M. Suárez-Calvet, C.William, D.H.Adamowicz,
K.J. Kopeikina, R. Pitstick, N. Sahara, K.H. Ashe, G.A. Carlson, et al.
2012. Propagation of tau pathology in a model of early Alzheimer’s
disease. Neuron. 73:685–697. http://dx.doi.org/10.1016/j.neuron.2011
.11.033
Eckermann, K., M.-M. Mocanu, I. Khlistunova, J. Biernat, A. Nissen, A.
Hofmann, K. Schönig, H. Bujard, A. Haemisch, E. Mandelkow, et al.
2007. The -propensity of Tau determines aggregation and synaptic
loss in inducible mouse models of tauopathy. J. Biol. Chem. 282:31755–
31765. http://dx.doi.org/10.1074/jbc.M705282200
Frost, B., R.L. Jacks, and M.I. Diamond. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284:12845–
12852. http://dx.doi.org/10.1074/jbc.M808759200
Guo, J.L., and V.M.-Y. Lee. 2011. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol.
Chem. 286:15317–15331. http://dx.doi.org/10.1074/jbc.M110.209296
Harris, J.A., A. Koyama, S. Maeda, K. Ho, N. Devidze, D.B. Dubal, G.-Q.
Yu, E. Masliah, and L. Mucke. 2012. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS ONE.
7:e45881. http://dx.doi.org/10.1371/journal.pone.0045881
Hochgräfe, K., and E.-M. Mandelkow. 2013. Making the brain glow: in vivo
bioluminescence imaging to study neurodegeneration. Mol. Neurobiol.
47:868–882. http://dx.doi.org/10.1007/s12035-012-8379-1
Iba, M., J.L. Guo, J.D. McBride, B. Zhang, J.Q. Trojanowski, and V.M.-Y.
Lee. 2013. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J. Neurosci.
33:1024–1037. http://dx.doi.org/10.1523/JNEUROSCI.2642-12.2013
Jack, C.R. Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner,
P.S. Aisen, L.M. Shaw, P. Vemuri, H.J. Wiste, S.D. Weigand, et al. 2013.
Tracking pathophysiological processes in Alzheimer’s disease: an updated
hypothetical model of dynamic biomarkers. Lancet Neurol. 12:207–216.
http://dx.doi.org/10.1016/S1474-4422(12)70291-0
Karch, C.M., A.T. Jeng, and A.M. Goate. 2012. Extracellular Tau levels are
influenced by variability in Tau that is associated with tauopathies. J. Biol.
Chem. 287:42751–42762. http://dx.doi.org/10.1074/jbc.M112.380642
Kfoury, N., B.B. Holmes, H. Jiang, D.M. Holtzman, and M.I. Diamond.
2012. Trans-cellular propagation of Tau aggregation by fibrillar species.

